[Combined chemotherapy with cisplatin and bleomycin for malignant tumor of the chest].
Twenty-two patients with malignant chest tumor, mainly primary lung cancer, were given 73 courses of combined administration of cisplatin and bleomycin. The following results were obtained. Of 13 evaluable patients one CR and four PR, with an overall response rate of 38.5% were observed. Of seven patients who received 3 courses or more, four showed therapeutic effect, producing a response rate of 57.1%. CR was obtained in a patient with a relapse of malignant germ cell tumor showing positive HCG and AFP preoperatively. The patient survived for 445 days after the start of this treatment. Of nine patients with non-small cell lung cancer in whom therapeutic effect could be evaluated, three PR, four MR, and two PD with a response rate of 33.3% were obtained. Side effects due to cisplatin such as nausea, vomiting and impairment of renal function were all transient. Furthermore, myelosuppression caused by this chemotherapy was relatively mild compared with other chemotherapy regimens.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D013724:Teratoma / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
D001761:Bleomycin; D002945:Cisplatin